1. Clinical Overview of CJC-1295 with DAC

Molecule: CJC-1295 with Drug Affinity Complex (DAC) is a long-acting GHRH analog designed to stimulate the pituitary gland to increase endogenous growth hormone (GH) secretion and IGF-1 production.

Key Features:

Long half-life (~6–8 days)
Stable midnight GH surge restoration
Minimal receptor desensitization
Does not suppress endogenous GH production
Promotes physiologic pulsatile GH release (unlike exogenous GH)

Primary Clinical Domains

Recovery and repair
Fat loss
Lean mass preservation
Sleep enhancement
Cognitive support
Hair, skin, and nail quality
Anti-aging and longevity

2. Mechanisms of Action

2.1 Growth Hormone–Releasing Hormone (GHRH) Receptor Activation

CJC-1295 binds to GHRH receptors on pituitary somatotrophs, triggering:

Increased GH synthesis & storage
Enhanced GH pulse amplitude
Improved IGF-1 formation in the liver

Clinical Benefit: Restores youthful GH rhythm while maintaining physiologic pulsatility.

2.2 DAC (Drug Affinity Complex) Technology

The DAC component binds to plasma proteins (primarily albumin), dramatically extending half-life:

Half-life: ~5–8 days vs minutes for native GHRH
Weekly or twice-weekly dosing
Stable GH/IGF-1 elevation

2.3 GH/IGF-1 Tissue-Level Benefits

Increases:

Protein synthesis
Collagen & extracellular matrix production
Bone turnover & density
Lipolysis & fat oxidation
Muscle fiber repair
Deep sleep architecture (especially slow-wave sleep)

2.4 Neurocognitive & Metabolic Effects

GH/IGF-1 axis enhances:

Memory consolidation
Insulin sensitivity
Mitochondrial function
Cellular repair pathways

3. Evidence Summary — Clinical Domains of Use

3.1 Fat Loss & Metabolic Improvement

GH improves:

Visceral fat reduction
Lipolysis during fasting
Lean body mass retention

CJC-1295 with DAC has been shown to increase IGF-1 by 1–3 fold, correlating with improved metabolic profile.

3.2 Muscle Recovery & Performance

Reported benefits:

Faster connective tissue healing
Enhanced muscle fiber repair
Decreased DOMS
Improved recovery windows

3.3 Sleep Quality

GH peaks during slow-wave sleep. Patients report:

Deeper sleep
Reduced nighttime awakenings
Improved morning alertness

3.4 Skin, Hair & Aesthetic Outcomes

GH/IGF-1 enhances:

Dermal thickness
Collagen synthesis
Hair quality
Nail integrity

Frequently used in anti-aging aesthetic protocols.

3.5 Longevity & Healthy Aging

GH decline with age leads to sarcopenia, increased visceral fat, impaired sleep and cognition, and reduced tissue repair. CJC-1295 partially reverses this decline through physiologic GH restoration.

4. Clinical Protocols

4.1 Reconstitution

CJC-1295 with DAC 5 mg vial
Add: 2 mL bacteriostatic saline → 2.5 mg/mL
or 1 mL saline → 5 mg/mL (more concentrated)
Gently roll, do not shake!

4.2 Administration

Subcutaneous (abdomen, flank, outer thigh)
Intramuscular also acceptable

4.3 Dosing Protocols

Standard Anti-Aging / Wellness

1–2 mg SC once weekly

Fat Loss / Metabolic Optimization

1 mg SC, 2× weekly (or 2 mg once weekly)

Performance & Recovery

2 mg SC once weekly or 1 mg SC twice weekly

Advanced Protocol / Severe GH Decline

2–2.5 mg SC twice weekly — Clinical discretion required.

4.4 Combination Therapy

CJC-1295 with DAC is commonly paired with:

Ipamorelin (GH secretagogue)
Tesamorelin (visceral fat)
BPC-157 / TB-500 (injury/repair)
AOD-9604 (fat loss)
Epitalon (longevity)

4.5 Duration of Therapy

12–24 weeks typical, up to 1 year under supervision
Many clinicians use quarterly cycling (12 weeks on / 4–6 weeks off)

5. Clinical Decision Trees

Decision Tree 1 — Candidate Evaluation

Age > 30 with symptoms of GH decline? → Yes

Poor sleep quality? → Yes

Low recovery capacity? → Yes

Visceral fat accumulation? → Yes

Contraindications? → Review

If ≥2 positive → CJC-1295 appropriate

Decision Tree 2 — Goal-Based Dosing

Fat loss → 1 mg twice weekly

Recovery → 2 mg weekly

Sleep optimization → 1 mg weekly

Anti-aging → 1–2 mg weekly

Athletic protocol → 2 mg weekly or split dosing

6. Safety & Contraindications

6.1 Contraindications

Active malignancy
Uncontrolled diabetes
Severe cardiovascular disease
Pregnancy / lactation
Hypersensitivity

6.2 Adverse Effects (Dose-Dependent)

Usually mild:

Water retention
Tingling or numbness
Mild joint stiffness
Increased appetite
Sleep intensity

Rare:

Carpal tunnel-like symptoms
Insulin sensitivity shifts (monitor in diabetics)

6.3 Monitoring Recommendations

Fasting glucose / A1c
IGF-1 (baseline and 6–8 weeks)
Lipids
Body composition
Sleep quality

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

CJC-1295 with DAC, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — CJC-1295 with DAC Clinical Reference Guide

GHRH Biology & Pharmacology

1. Thorner, M. O., Vance, M. L. The growth hormone–releasing hormone axis. New England Journal of Medicine, 309, 408–415 (1993).

2. Bowers, C. Y. GH-releasing peptides and GHRH analogs: Mechanisms and synergy. Endocrine Reviews, 19(5), 541–575 (1998).

3. Walker, R. F. Growth hormone secretagogues: Interactions with GHRH pathways. Journal of Clinical Endocrinology & Metabolism, 84(7), 2281–2286 (1999).

CJC-1295 Clinical & Pre-Clinical Data

4. Teichman, S. L., et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805 (2006).

5. Ionescu, M., et al. Combined administration of CJC-1295 and GH secretagogues. Growth Hormone & IGF Research, 16(6), 324–331 (2006).

6. Fahy, B. G., et al. Long-acting GHRH analogs and metabolic effect profiles. Clinical Pharmacology & Therapeutics, 80(2), 159–168 (2006).

GH & IGF-1 Effects on Composition, Sleep & Longevity

7. Rudman, D., et al. GH effects on body composition in aging adults. New England Journal of Medicine, 323, 1–6 (1990).

8. Maggio, M., et al. GH/IGF-1 signaling in aging and sarcopenia. Endocrine Reviews, 33(3), 380–407 (2012).

9. Van Cauter, E., et al. GH secretion and sleep physiology. Sleep, 21(3), 253–260 (1998).

Peptide Safety & Endocrine Modulation

10. Jaffe, C. A. Physiology and pharmacology of GH releasing peptides. Endocrinology & Metabolism Clinics, 31, 135–167 (2002).

11. Melmed, S. Safety considerations in GH axis modulation. Nature Reviews Endocrinology, 6, 367–377 (2010).